Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives $15.00 Average PT from Brokerages

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have earned an average rating of “Reduce” from the seven research firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $15.00.

A number of brokerages have commented on IART. Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. boosted their target price on shares of Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. Truist Financial restated a “hold” rating and issued a $13.00 target price (down previously from $15.00) on shares of Integra LifeSciences in a report on Monday, November 3rd. Finally, Citigroup cut their price target on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a research note on Friday, October 31st.

Integra LifeSciences Price Performance

IART stock opened at $12.34 on Friday. The company has a market capitalization of $961.16 million, a P/E ratio of -1.91 and a beta of 1.02. The company has a fifty day moving average price of $12.67 and a 200-day moving average price of $13.45. The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.80 and a current ratio of 3.14. Integra LifeSciences has a 52-week low of $10.87 and a 52-week high of $27.13.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.11. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 14.06%. The firm had revenue of $402.06 million during the quarter, compared to analyst estimates of $414.31 million. During the same quarter last year, the business earned $0.41 EPS. The company’s revenue was up 5.6% compared to the same quarter last year. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS and its FY 2025 guidance at 2.190-2.240 EPS. As a group, equities analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

Insider Activity at Integra LifeSciences

In other Integra LifeSciences news, Director Jeffrey A. Graves bought 9,000 shares of the business’s stock in a transaction dated Wednesday, November 5th. The shares were purchased at an average price of $11.35 per share, for a total transaction of $102,150.00. Following the purchase, the director directly owned 41,086 shares of the company’s stock, valued at approximately $466,326.10. This represents a 28.05% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.54% of the stock is currently owned by corporate insiders.

Institutional Trading of Integra LifeSciences

Hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after buying an additional 1,975 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Integra LifeSciences during the 1st quarter worth $277,000. Goldman Sachs Group Inc. grew its stake in shares of Integra LifeSciences by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after acquiring an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Integra LifeSciences by 23.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after acquiring an additional 45,693 shares during the last quarter. Finally, Strs Ohio bought a new stake in Integra LifeSciences in the 1st quarter valued at about $400,000. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.